SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.sabbiotherapeutics.com/2021/10/04/sab-biotherapeutics-announces-first-patient-dosed-in-phase-3-nih-activ-2-trial-evaluating-sab-185-for-treatment-of-covid-19/
Research Institution
SAB Biotherapeutics
Short Title
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald